- Home
- ETON vs NPCT Comparison
ETON vs NPCT Comparison
Compare ETON & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- NPCT
- Stock Information
- Founded
- ETON 2017
- NPCT 2020
- Country
- ETON United States
- NPCT United States
- Employees
- ETON N/A
- NPCT N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- ETON Health Care
- NPCT Finance
- Exchange
- ETON Nasdaq
- NPCT Nasdaq
- Market Cap
- ETON 329.8M
- NPCT 308.5M
- IPO Year
- ETON 2018
- NPCT N/A
- Fundamental
- Price
- ETON $14.51
- NPCT $10.85
- Analyst Decision
- ETON Strong Buy
- NPCT
- Analyst Count
- ETON 3
- NPCT 0
- Target Price
- ETON $24.00
- NPCT N/A
- AVG Volume (30 Days)
- ETON 330.6K
- NPCT 107.1K
- Earning Date
- ETON 03-13-2025
- NPCT 01-01-0001
- Dividend Yield
- ETON N/A
- NPCT 9.82%
- EPS Growth
- ETON N/A
- NPCT N/A
- EPS
- ETON N/A
- NPCT N/A
- Revenue
- ETON $34,677,000.00
- NPCT N/A
- Revenue This Year
- ETON $22.19
- NPCT N/A
- Revenue Next Year
- ETON $110.87
- NPCT N/A
- P/E Ratio
- ETON N/A
- NPCT N/A
- Revenue Growth
- ETON 5.64
- NPCT N/A
- 52 Week Low
- ETON $3.03
- NPCT $8.58
- 52 Week High
- ETON $18.41
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- ETON 41.72
- NPCT 55.61
- Support Level
- ETON $14.18
- NPCT $10.76
- Resistance Level
- ETON $17.13
- NPCT $10.97
- Average True Range (ATR)
- ETON 1.03
- NPCT 0.07
- MACD
- ETON -0.50
- NPCT -0.00
- Stochastic Oscillator
- ETON 7.80
- NPCT 56.99
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.